Hence, GRK2 inhibition for the treatment of HF is not far from application in clinical trials: gene therapy with AAV6-βARKct will occur in the near future while GRK2 inhibition by small molecules would be an intriguing option, as well. Here, GRK2 is linked to hydrops fetalis.